Verano Holdings (VRNO) Equity Income (2022 - 2023)
Verano Holdings (VRNO) reported Equity Income of -$45000.0 for Q3 2023, up 78.47% year-over-year from -$25214.5 in Q3 2022, and up 55.45% quarter-over-quarter from -$101000.0 in Q2 2023.
Verano Holdings (VRNO) Equity Income (2022 - 2023) Analysis & Trends
Verano Holdings (VRNO) has 2 years of Equity Income data on file, last reported at -$45000.0 in Q3 2023.
- Equity Income for Q3 2023 came in at -$45000.0, up 78.47% year-over-year; the trailing twelve-month figure through Jun 2024 was -$45000.0 (up 92.01% YoY), and the FY2023 annual result was -$306000.0, down 119.64% from the prior year.
- Equity Income grew to -$45000.0 in Q3 2023 per VRNO's latest filing, from -$101000.0 in the prior quarter.
- Over five years, Equity Income peaked at -$45000.0 in Q3 2023 and troughed at -$209000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -1.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 25.30 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -9.68 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 14.91 Mn |
| 10 | Verano Holdings | - | - | 98.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -45,000.00 |
| Jun 30, 2023 | -101,000.00 |
| Mar 31, 2023 | -160,000.00 |
| Dec 31, 2022 | -93,000.00 |
| Sep 30, 2022 | -209,000.00 |